pharmaceutical

Last January, Anderson Ata became the seventh person in the world to receive teplizumab, which researchers say is the first big milestone in treating diabetes since the production of insulin over 100 years ago.

The drug had been fast-tracked for approval under the agency's accelerated approval program, and has been available for more than a decade, despite the drugmaker's failure to prove that it works.

Drugmakers long ceased to be the only villain of the insulin price scandal. While Lilly is cutting the list price” and others may follow, will other "parties" (i.e. pharmacy benefit managers) cause this price to increase before it hits the pharmacy counter?

WeightWatchers' acquisition of a telehealth company is just the latest commercial push into the market for a new generation of medications that promise significant weight loss.

U.S. doctors can now choose Amjevita instead, the first of several close copies of the popular rheumatoid arthritis drug expected this year. But industry-watchers warn consumer savings may be limited.

Moffitt Cancer Center in Tampa helped study the imaging drug, which the FDA recently approved. It draws attention to hard-to-spot tumors during surgery.

A new Alzheimer's drug isn't reaching many patients. Doctors say reasons include its high cost, and lingering questions about its effectiveness.

The New York attorney general says Johnson & Johnson has agreed to pay $230 million to settle claims that the pharmaceutical giant helped fuel the opioid crisis.

At issue is a provision that requires physicians to have in-person consultations with patients before prescribing obesity-treatment drugs, which is inconsistent with the state’s telehealth law.

The agency is to decide by Monday whether to greenlight Biogen’s drug aducanumab, despite a near-unanimous rejection of the product by an FDA advisory committee of outside experts in November.